Alexander Spira, MD, Next Oncology-Virginia VCS, Fairfax, VA, discusses findings from the Phase Ia/b STK-012-101 trial (NCT05098132) of STK-012, a novel α/β-IL-2R biased partial agonist, in advanced solid tumors. Manageable adverse events with no dose-limiting toxicities were observed and notable efficacy signals include partial responses in anti-PD-1 refractory non-small cell lung cancer (NSCLC), with ongoing dose expansion studies. STK-012 demonstrates distinct pharmacokinetic and pharmacodynamic profiles, supporting its selectivity for IL-2R α/β and warranting further investigation. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть